Repotrectinib
Augtyro · ROS1/TRK TKI
2023 ROS1 inhibitor; creatinine rise via secretion block.
Ibtrozi · ROS1 TKI; pseudo-AKI
ROS1 TKI · approved 2025 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Next-generation ROS1 TKI with a benign, transporter-mediated creatinine bump
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Drug-specific renal toxicity data for taletrectinib are limited. In the pooled TRUST-I and TRUST-II registrational safety population (352 patients at 600 mg once daily), the dominant treatment-emergent events were gastrointestinal and hepatic (elevated AST/ALT), with no defined intrinsic kidney lesion; renal-specific incidence figures are not separately reported. The expected renal signal, extrapolated from the ROS1/TRK-TKI class, is a mild, benign rise in serum creatinine from inhibition of tubular creatinine secretion rather than true GFR loss (pseudo-AKI). A precise incidence for taletrectinib-attributable creatinine elevation is not established.Source: 40179330
A class-effect transporter-mediated creatinine rise appears early after initiation and plateaus, though drug-specific timing is not separately characterized.
Distilled from: “Class-effect transporter inhibition produces a creatinine rise early after initiation that tends to plateau and is dose-dependent. Drug-specific onset timing for taletrectinib is not separately characterized.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Taletrectinib is an oral, CNS-active, selective next-generation ROS1 tyrosine kinase inhibitor. It binds the ATP pocket of the ROS1 kinase domain to block constitutive signaling driven by ROS1 gene fusions, and retains activity against the solvent-front G2032R resistance mutation that defeats earlier-generation agents. It has more selective ROS1 inhibition with reduced TRK-related off-target activity compared with some predecessors.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the ROS1 TKI class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 120 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
15 of 120 reports
Reported with hospitalization
37 of 120 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Taletrectinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Augtyro · ROS1/TRK TKI
2023 ROS1 inhibitor; creatinine rise via secretion block.
Rozlytrek · TRK/ROS1 TKI
Creatinine rise via reduced tubular secretion.
Vitrakvi · TRK inhibitor
Mild creatinine rise; generally well tolerated.
Tukysa · HER2 TKI
Benign creatinine rise via tubular secretion inhibition.
Rubraca · PARP inhibitor
Transporter-mediated creatinine rise.
Talzenna · PARP inhibitor
Renally cleared; creatinine rise.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.